Key statistics
On Friday, Exelixis Inc (E2XE34:SAO) closed at 72.80, -0.88% below its 52-week high of 73.45, set on Aug 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 73.15 |
---|---|
High | 73.45 |
Low | 72.80 |
Bid | 72.59 |
Offer | 73.22 |
Previous close | 72.80 |
Average volume | -- |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Aug 30 2024 20:49 BST.
More ▼
Press releases
- Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
- Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
- Invenra Highlights Exelixis’ Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors
- Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
- Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
More ▼